Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Equity: 2019-2025

Historic Return on Equity for Allogene Therapeutics (ALLO) over the last 6 years, with Sep 2025 value amounting to -0.64%.

  • Allogene Therapeutics' Return on Equity fell 7.00% to -0.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.64%, marking a year-over-year decrease of 7.00%. This contributed to the annual value of -0.55% for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q3 2025, Allogene Therapeutics' Return on Equity stood at -0.64%, which was up 0.68% from -0.64% recorded in Q2 2025.
  • Allogene Therapeutics' Return on Equity's 5-year high stood at -0.19% during Q4 2021, with a 5-year trough of -0.64% in Q2 2025.
  • For the 3-year period, Allogene Therapeutics' Return on Equity averaged around -0.58%, with its median value being -0.57% (2024).
  • Its Return on Equity has fluctuated over the past 5 years, first climbed by 12bps in 2021, then declined by 30bps in 2023.
  • Allogene Therapeutics' Return on Equity (Quarterly) stood at -0.19% in 2021, then dropped by 28bps to -0.47% in 2022, then decreased by 10bps to -0.57% in 2023, then fell by 1bps to -0.57% in 2024, then declined by 7bps to -0.64% in 2025.
  • Its Return on Equity stands at -0.64% for Q3 2025, versus -0.64% for Q2 2025 and -0.62% for Q1 2025.